Bioventus
Update in progressBVS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Bioventus is a medical device company focused on pain relief and musculoskeletal therapies worldwide. Its portfolio includes intra-articular and hyaluronic acid injections (Durolane, GELSYN-3, SUPARTZ), peripheral nerve stimulation (Stimrouter, TalisMann) and the XCELL PRP System. It also offers ultrasonic and bone fusion tools (neXus, BoneScalpel, SonaStar, SonicOne) and bone grafts (Osteoamp, Reficio, Purebone, Signafuse). Exogen supports fracture healing. Founded 2011, Durham, NC.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.24
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Robert E. Claypoole
- Founded2011
- Employees950
- Websitewww.bioventus.com
Identifiers
- ISINUS09075A1088
- FIGIBBG00D8550B3
- CUSIP09075A108
- CIK0001665988